Authors

Latest:

Dr. Acuna-Villaorduna on the Increase of Early-Onset CRC Diagnoses

Ana Acuna-Villaorduna, MD, Heme/Oncology fellow at Montefiore Medical Center/Albert Einstein College of Medicine, discusses the increase of early-onset colorectal cancer, specifically in African-American and Hispanic populations.

Ana M. Gonzalez-Angulo, MD

Latest:

Triple Receptor-Negative Breast Cancer: Current and Future Treatments

Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.

Ana M. Molina, MD

Latest:

Dr. Molina on Information for the Public on Kidney Cancer

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, shares information that she feels the public should know about kidney cancer.

Ana Oaknin, MD

Latest:

Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.

Ana Stojanovska, BS

Latest:

NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management

Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.

Anand B. Karnad, MD

Latest:

Cancer Disparities Heighten Need to Recruit Hispanics for Clinical Trials

The Hispanic population in the United States represents the fastest-growing segment of the population (expected to reach 30% of the nation's total by 2050), and faces significant cancer health disparities

Anas

Anas Al-Janadi, MD

Latest:

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Anas Younes, MD

Latest:

Dr. Younes Discusses the Future of CAR T-Cell Therapy

Anas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Anas Younes, MD, Memorial Sloan Kettering Cancer Center

Anastasios Raptis, MD

Latest:

Dr. Raptis on DRd in Newly Diagnosed Multiple Myeloma

Anastasios Raptis, MD, a clinical assistant professor of medicine at the University of Pittsburgh School of Medicine Hillman Cancer Center, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in the treatment of patients with newly diagnosed multiple myeloma.

Anastasios (Tassos) Dimou, MD

Latest:

Dr. Dimou on Managing Disease Progression in NSCLC

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

and Anas Younes, MD, MSKÂ

Anders Mellemgaard, MD, Herlev University Hospital

Anders Neijber, MD, PhD, MBA

Latest:

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

Latest:

Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC

A review by AndrÃ© P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.

Andre Goy, MD, John Theurer Cancer Center

Latest:

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, Hackensack University Medical Center

Andre Goy, MD, MS

Latest:

Progress in Immunotherapy and Precision Medicine: Key Insights from JTCC at ASH 2024

Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is shaping the future of cancer treatment, with key insights from the JTCC highlighting emerging therapies and their potential to improve patient outcomes through personalized approaches.

Andre Goy, MD, MS, John Theurer Cancer Center